Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNIFY: Midostaurin in FLT3-Negative AML
NCT03512197Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2018
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of midostaurin in acute myeloid leukemia (AML), sponsored by Novartis. Started Jul 2018; status: completed.
02
Drugs
midostaurin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03512197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03512197.